Conditional Survival of Esophageal Cancer An Analysis from the SEER Registry (1988–2011)  by Kim, Ellen et al.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1490 Journal of Thoracic Oncology ®  •  Volume 10, Number 10, October 2015
Introduction: Conditional survival can provide valuable predictive 
information for both patients and caregivers for patients surviving 
over time. The purpose of this study was to estimate conditional sur-
vival for esophageal cancer patients through analysis of a national 
population-based cancer registry.
Methods: This retrospective cohort study analyzed 64,433 patients 
within the Surveillance, Epidemiology, and End Results (SEER) 
data set who were diagnosed with esophageal cancer from 1988 to 
2011. Covariates included cancer characteristics and demographics. 
Overall survival (defined as time from diagnosis until death), cause-
specific survival (defined as time from diagnosis until death from 
cancer), and 5-year conditional survivals (the probability of surviv-
ing an additional 5 years) were calculated. Significant prognostic 
variables of univariate and multivariable models of survival were 
identified.
Results: The multivariable models of overall and cause-specific 
survivals included gender, age group, race, relationship status, year 
of diagnosis, site, grade, histology, and stage group. Although all 
patients showed an improvement in conditional survival over time, 
more dramatic improvements were seen in more advanced stage 
groups. At the 5-year mark, conditional cause-specific survival of 
distant stage (defined as having spread by direct extension or metas-
tasis to distant organs, tissues, or lymph nodes) increased from 4% to 
79%, whereas regional stage increased from 18% to 77% and local-
ized stage increased from 38% to 85%.
Conclusions: Conditional survival showed improving prognosis over 
time. Patients with advanced stage had the most dramatic improve-
ment. Clinicians, caregivers, and patients with esophageal cancer can 
feel encouraged by the improving prognosis with each year survived. 
This information has practical implications regarding longitudinal 
follow-up guidelines and survivorship planning.
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Esophageal cancer is the eighth most common cancer and sixth leading cause of cancer death worldwide, with more 
than 400,000 diagnoses and 350,000 deaths annually.1 In the 
United States, an estimated 18,170 new cases were diagnosed 
in 2014 and median age of diagnosis was 67 years.2 Incidence 
rates have been increasing, especially in adenocarcinoma his-
tology and white race.1 Although survival of esophageal can-
cer has improved over the decades,1 5-year relative survival 
was still only 17% in 2014 in the United States. Prognosis 
depends heavily on stage and the individual’s response to 
treatment, but prognosis also changes for each individual over 
time. Conditional survival demonstrates quantitatively and 
visually how an individual’s prognosis changes over time.
The purpose of this study was to calculate the condi-
tional survival of esophageal cancer patients in the United 
States. The hypothesis was that conditional survival would 
improve over time, especially in more advanced stages, as 
has been shown for other gastrointestinal tract tumors like the 
stomach,3 colon,4 and rectum.5 The national population-based 
Surveillance, Epidemiology, and End Results (SEER) registry 
is a publicly available database that provides both large cohort 
size and long-term follow-up, two necessary components for 
studying conditional survival. These attributes are especially 
useful for esophageal cancer whose epidemiologic study can 
be difficult because of the short survival.6
MATERIALS AND METHODS
The data were obtained from the SEER registry of the 
National Cancer Institute (Bethesda, MD). SEER is a national 
population-based cancer registry that is globally recognized 
for its accuracy and completeness. It currently collects cancer 
incidence and survival data for over one fourth of the United 
States population.7 More information on the geographic 
regions included as SEER regions can be found at its website.7 
Because the data from the SEER registry are de-identified and 
publicly available, no institutional review board approval was 
necessary.
The newest available SEER registry (1973–2011) found 
81,686 patients who were diagnosed with esophageal cancer as 
their first and only cancer diagnosis using Collaborative Stage 
Schema. The anatomical sites included both the esophagus 
and esophagus/gastroesophageal junction (GEJ). Inclusion 
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required microscopic diagnostic confirmation, malignant 
tumor behavior, active follow-up, and diagnosis after the year 
1988 to have sufficient information for analysis. Cases were 
excluded if reported by death certificate, autopsy, or hospice. 
Pediatric cases were excluded (age at diagnosis <18 years). 
These criteria resulted in 64,433 cases in the final retrospec-
tive cohort analysis.
Covariates included demographic variables (gender, age 
group, race, and marital status) and diagnostic information (year 
of diagnosis, site, grade, histology, and SEER historic stage 
group). SEER historic stage grouped esophageal cancers into 
localized, regional, distant, or unknown stages as follows: (1) 
localized—an invasive neoplasm confined entirely to the organ 
of origin; (2) regional—a neoplasm that has extended directly 
into surrounding organs or tissues, into regional lymph nodes, 
or both; (3) distant—a neoplasm that has spread to parts of the 
body remote from the primary tumor either by direct extension 
or by discontinuous metastasis (e.g., implantation or seeding) to 
distant organs, tissues, or through the lymphatic system to distant 
lymph nodes; or (4) unknown—information is not sufficient to 
assign a stage. To maximize sample size, all sites (esophagus and 
esophagus/GEJ), grades (I–IV, unknown), and histology (adeno-
carcinoma, squamous cell carcinoma, all others) were included. 
Esophagus site can be loosely correlated with multiple regions 
(cervical, upper thoracic, and mid thoracic). The lower (distal) 
esophagus and GEJ site can be considered as the lower thoracic 
region. Patients were divided into two age groups around 65 
years, a typically used definition of elderly patients according 
to the World Health Organization.8 Race categories were white, 
black, other (American Indian/Alaska native, Asian/Pacific 
Islander, or other unspecified), and unknown. Relationship sta-
tus categories were single, married/partner, separated/divorced, 
widowed, and unknown. The χ2 test was used to compare the 
distribution of these groups across the stage groups.
The Kaplan–Meier method was used for the initial, 
unadjusted univariate survival analysis. Overall survival was 
defined as time from diagnosis until death. Cause-specific 
survival was defined as time from diagnosis until death 
because of esophageal cancer. The log-rank test was used to 
identify and compare the outcome of significant covariates 
in univariate survival analysis. These clinically meaning-
ful and significant prognostic variables were considered for 
inclusion in the final Cox proportional hazards multivariable 
regression models. 
Five-year conditional (overall and cause specific) surviv-
als were calculated for each of the covariates in the final multi-
variable regression models. Conditional survival was calculated 
as the proportion surviving 5 additional years, as shown in the 
following equation: when S(t) is (overall or cause specific) sur-
vival at time t, conditional survival is S(x + 5)/S(x).
Analysis was conducted using SAS v9.3 and Microsoft 
Excel 2010. Conditional overall survival was also calculated 
for the subgroup of patients diagnosed during 2004 to 2011 
with an American Joint Committee on Cancer (AJCC) 6th 
edition stage, to compare trends using SEER historic stage 
versus AJCC stage. Effort was made to present only condi-
tional survival graphs with sufficient follow-up by displaying 
conditional survivals of only those values calculated from 
Kaplan––Meier survival estimates with at least 100 patients 
at risk; exceptions were required for unknown marital status 
(<100 cases at risk at 9 years after diagnosis, which was neces-
sary for conditional survivals at ≥4 years) and for subanalysis 
of cases diagnosed after 2004 (because of fewer cases, shorter 
follow-up, and poor survival).
RESULTS
Stage distribution was statistically different across all 
demographic and diagnostic covariates, as shown in Table 1; 
all p values from χ2 test were less than 0.0001. For all stages, 
there were more patients with male gender, white race, mar-
ried, diagnosed in 2000 to 2011, non-GEJ site, grades II and 
III, and adenocarcinoma histology. Relatively lower stage 
was associated with female gender, older age group, white or 
unknown race, widowed or unknown relationship status, non-
GEJ site, lower grade, and squamous cell histology. Diagnosis 
during 2000 to 2011 was associated with fewer unknown stage 
and more distant stage group diagnoses.
Analysis of univariate overall and cause-specific sur-
vivals showed that better survival was associated with more 
distal site, lower stage, lower grade, adenocarcinoma histol-
ogy, more recent diagnosis, younger age at diagnosis, and 
being married or non-widowed; all p values from log-rank 
test for significance were less than 0.0001. Five-year cause-
specific versus overall survival of localized stage was 38% 
versus 29%; regional stage was 18% versus 15%; and dis-
tant stage was 4% versus 3%. Ten-year cause-specific ver-
sus overall survival of localized stage was 32% versus 19%; 
regional stage was 14% versus 9%; and distant stage was 3% 
versus 2%.
All of the covariates were also found to be significant in 
multivariable analysis, as shown in Table 2. Better prognosis 
was associated with younger age at diagnosis, non-black race, 
married or non-widowed relationship status, diagnosed in 
2000 to 2011, more distal site, lower grade, adenocarcinoma 
histology, and lower stage after adjusting for other covari-
ates. The single greatest hazard in the multivariable model 
was distant stage, with triple the risk of death compared with 
localized stage, and 3.5 times the risk of death from cancer 
compared with localized stage.
Conditional overall and cause-specific survivals of 
all patients improved dramatically over time, as shown 
in Figure 1A and B. Over the first 5 years after diagnosis, 
conditional overall survival improved from 29% to 67% in 
the localized stage group, 15% to 63% in the regional stage 
group, and 3% to 68% in the distant stage group (Fig. 1A). 
Over the first 5 years after diagnosis, conditional cause-spe-
cific survival improved from 38% to 85% in the localized 
stage group, 18% to 77% in the regional stage group, and 
4% to 79% in the distant stage group (Fig. 1B). Subanalysis 
of the 3338 cases with AJCC 6th edition staging informa-
tion showed the same trend, with conditional overall sur-
vival of stage IV increasing from 3% to 52% after 3 years, 
whereas stages III/II/I increased from 11%/25%/34% to 
52%/68%/68%, respectively (Fig. 2), although there were 
fewer cases in this analysis. More dramatic increases were 
seen in more advanced stages.
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A similar trend was seen in conditional overall and 
cause-specific survivals of the higher grade group as well 
(Fig. 3A and B). When grouped by site (Supplementary 
Figure 1, Supplemental Digital Content 1, http://links.
lww.com/JTO/A869), histology (Supplementary Figure 
2, Supplemental Digital Content 2, http://links.lww.com/
TABLE 1.  Demographic and Cancer Diagnosis Distribution of Studied Cohort by Stage Group
Localized Regional Distant Unknown Total P Value
Gender Female 3529 4050 4490 2516 14,585 <0.0001
% 24 28 31 17
Male 10,592 15,345 18,524 5387 49,848
% 21 31 37 11
Age group <65 5170 9241 11,948 2271 28,630 <0.0001
% 18 32 42 8
65+ 8951 10,154 11,066 5632 35,803
% 25 28 31 16
Race White 11,832 16,158 19,066 6318 53,374 <0.0001
% 22 30 36 12
Black 1467 2000 2526 1053 7046
% 21 28 36 15
Other/ unknown 822 1237 1422 532 4013
% 20 32 36 12
Marital status Single 1768 2629 3507 1173 9077 <0.0001
% 19 29 39 13
Married/partner 8152 11,782 13,570 3476 36,980
% 22 32 37 9
Separated/divorced 1311 2117 2673 729 6830
% 19 31 39 11
Widowed 2266 2269 2501 1847 8883
% 26 26 28 21
Unknown 624 598 763 678 2663
% 23 22 29 25
Year of diagnosis 1988–1999 3926 5262 5358 3086 17,632 <0.0001
% 22 30 30 18
2000–2011 10,195 14,133 17,656 4817 46,801
% 22 30 38 10
Site Esophagus 9597 13,050 14,896 5876 43,419 <0.0001
% 22 30 34 14
Esophagus/GEJ 4524 6345 8118 2027 21,014
% 22 30 39 10
Grade I 1145 715 618 396 2874 <0.0001
% 40 25 22 14
II 5146 6339 6268 2401 20,154
% 26 31 31 12
III/IV 5262 10,052 12,224 3188 30,726
% 17 33 40 10
Unknown 2568 2289 3904 1918 10,679
18 32 40 10
Histology Adenocarcinoma 8622 11,339 14,517 3928 38,406 <0.0001
% 22 30 38 10
Squamous cell 4030 5491 5193 2769 17,483
% 23 31 30 16
All others 1469 2565 3304 1206 8544
% 17 30 39 14
All p values were less than 0.0001 by χ2 test.
GEJ, gastroesophageal junction.
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JTO/A870), year of diagnosis (Supplementary Figure 3, 
Supplemental Digital Content 3, http://links.lww.com/JTO/
A871), gender (Supplementary Figure 4, Supplemental 
Digital Content 4, http://links.lww.com/JTO/A872), age 
at diagnosis (Supplementary Figure 5, Supplemental 
Digital Content 5, http://links.lww.com/JTO/A873), race 
(Supplementary Figure 6, Supplemental Digital Content 6, 
http://links.lww.com/JTO/A874), or relationship status 
(Supplementary Figure 7, Supplemental Digital Content 7, 
http://links.lww.com/JTO/A875), the conditional survivals 
increased more uniformly so that the relative relationship 
between subgroups was maintained over time.
DISCUSSION
This is the first analysis to describe overall conditional 
and cause-specific survival for esophageal cancer. Two studies 
TABLE 2.  Final Cox Proportional Hazards Model Multivariable Regression with Effect Estimates for Overall Survival (Defined as 
Time from Diagnosis until Death from All Causes) and Cause-Specific Survival (Defined as Time from Diagnosis until Death due 
to Cancer)
Overall Survival Cause-Specific Survival
Hazard  
Ratio
95% Confidence 
Interval of Hazard 
Ratio P Value
Hazard  
Ratio
95% Confidence 
Interval of Hazard 
Ratio P Value
Gender
  Female 1 (baseline) 1 (baseline)
  Male 1.1 1.09–1.14 <0.0001 1.1 1.07–1.12 <0.0001
Age group
  <65 1 (baseline) 1 (baseline)
  65+ 1.4 1.40–1.45 <0.0001 1.3 1.31–1.36 <0.0001
Race
  White 1 (baseline) 1 (baseline)
  Black 1.2 1.12–1.19 <0.0001 1.1 1.10–1.17 <0.0001
  Other 0.9 0.84–0.91 <0.001 0.9 0.84–0.91 <0.0001
  Unknown 0.6 0.53–0.73 <0.0001 0.6 0.50–0.72 <0.0001
Relationship status
  Single 1 (baseline) 1 (baseline)
  Married/partner 0.8 0.79–0.83 <0.0001 0.8 0.80–0.84 <0.0001
  Separated/divorced 1.0 0.94–1.01 0.17 1.0 0.94–1.01 0.1536
  Widowed 1.1 1.06–1.13 <0.0001 1.1 1.06–1.14 <0.0001
  Unknown 0.9 0.87–0.96 0.0001 0.9 0.87–0.97 0.001
Year of diagnosis
  1988–1999 1 (baseline) 1 (baseline)
  2000–2011 0.8 0.80–0.83 <0.0001 0.8 0.79–0.83 <0.0001
Site
  Esophagus 1 (baseline) 1 (baseline)
  Esophagus/GEJ 1.0 0.94–0.98 0.0003 1.0 0.94–0.98 <0.0001
Grade
  I 1 (baseline) 1 (baseline)
  II 1.2 1.14–1.25 <0.0001 1.2 1.18–1.30 <0.0001
  III/IV 1.4 1.33–1.46 <0.0001 1.5 1.41–1.56 <0.0001
  Unknown 1.2 1.17–1.28 <0.0001 1.3 1.21–1.34 <0.0001
Histology
  Adenocarcinoma 1 (baseline) 1 (baseline)
  Squamous cell 1.1 1.12–1.17 <0.0001 1.1 1.12–1.17 <0.0001
  All others 1.1 1.11–1.17 <0.0001 1.2 1.12–1.19 <0.0001
Stage
  Localized 1 (baseline) 1 (baseline)
  Regional 1.4 1.38–1.45 <0.0001 1.6 1.54–1.63 <0.0001
  Distant 3.0 2.91–3.06 <0.0001 3.5 3.44–3.63 <0.0001
  Unknown 2.0 1.90–2.02 <0.0001 2.1 2.05–2.20 <0.0001
GEJ, gastroesophageal junction.
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of perioperative mortality published what they called condi-
tional survival: one following esophagectomy or gastrectomy 
for esophagogastric cancer9 and another following surgery for 
non-metastatic colon, esophageal, gastric, liver, lung, pan-
creatic, or rectal cancers.10 What they actually calculated was 
survival excluding perioperative mortality (survival among 
patients who did not die within 30 or 60 days of surgery). 
These are different from the more standard 5-year conditional 
survival calculated here.
A meeting abstract by German investigators calculated 
conditional survival using 25,306 SEER cases diagnosed 
between 1988 and 2004.11 It is unclear from the abstract 
exactly what selection criteria or analytical methods they 
used. Their “multivariate [sic]” analysis does not seem to have 
included stage, site, grade, histology, year of diagnosis, or age 
group. Dubecz et al.11 showed the same dramatic increase in 
conditional overall survival in more advanced stages, with 
slightly lower conditional survival values (58%, 56%, and 
FIGURE 1.  Five-year conditional 
overall survival (A) and cause-specific 
survival (B) of esophageal cancer 
patients by SEER historic stage group, 
calculated from Kaplan–Meier survival 
estimates, with diagonal labels above 
the bars showing overall survival and 
cause-specific survival from diagnosis, 
respectively.
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61% for localized, regional, and distant SEER historic stages 
after 5 years, compared with the current, larger analysis, 67%, 
63%, and 68%, respectively). Other gastrointestinal tract3–5 
and solid tumors12–15 show a similar pattern, with the 5-year 
conditional survival of higher stage disease increasing more 
rapidly and starting to approach the conditional survivals of 
lower stages over time. As shown in Figure 1B, although con-
ditional cause-specific survival of distant stage increases from 
4% to 15% after just 1 year, this is only for the 24% who sur-
vive for 1 year. Likewise, although conditional cause-specific 
survival of distant stage increases to almost 20-fold over 5 
years (from 4% to 79%), this is only for the 4% who are still 
alive at the 5-year mark following the original diagnosis.
Our higher survivals are reasonable given that Dubecz 
et al.11 used an older release of the same SEER registry. 
Patients diagnosed in 2000 to 2011 had better outcomes than 
those from 1988 to 1999 in both univariate and multivariable 
survival analyses. This is consistent with established national 
trends1 and is likely a result of a combination of factors includ-
ing advances in treatment methods, better use of combined 
modalities, and changes in dominant histology type. Incidence 
of adenocarcinoma has been increasing while that of squa-
mous cell carcinoma has been decreasing1; adenocarcinoma 
had better overall and cause-specific survivals than squamous 
cell carcinoma in both univariate and multivariable survival 
analyses.
There are many possible reasons for the greater increase 
in conditional survival for more advanced stages. Stage is 
thought to be the single most important prognostic factor.1 
In our multivariable analysis as well, the largest predictors of 
hazard were advanced stages (Table 2). Unlike localized or 
regional stages, distant stage includes a much wider spectrum 
of disease; distant stage could mean one distant lymph node, 
or it could mean widely metastatic cancer. In a subanalysis 
of cases diagnosed after 2004, when SEER started including 
AJCC 6th edition stage, localized stage group was mostly stage 
I (ranging stages I and II), regional stage group was mostly 
stages II and III (ranging stages I–IV), and distant stage group 
was mostly stage IV (ranging stage I–IV). This would exac-
erbate the range in therapies received by patients with distant 
stage because of different treatment options, aggressiveness of 
and patients’ tolerance of these treatments, and varying goals 
of treatment. Initial mortality was high from more advanced 
stages, with 1-year cause-specific survival of only 24%, but 
the patients who did survive 1 or 2 years may have been those 
with relatively less severe disease and thus better survival.
SEER can provide data to quantify the potential impact 
of different modalities and their sequence of administration 
including preoperative therapy.16 The generation of outcome 
prediction tools using these data may serve as decision aids for 
patients and practitioners.16,17 One limitation of using SEER 
data is the lack of detailed treatment information. Treatment 
information is limited to surgery or radiation therapy received 
within 4 months of diagnosis; it does not have treatments 
started later or details on the specific agents that comprised 
systemic therapies. Dubecz et al.11 included surgery as a 
covariate, but we did not feel that there were adequate details 
regarding surgery or other treatment information to include it 
in the analysis without potentially compromising the quality 
of the results because of incomplete treatment information.
The grade may not be as reliable as some of the other 
tumor characteristics because central pathology review was 
not and cannot be performed for all of the cases in the SEER 
database. Another limitation is the inconsistency of staging 
information and potential understaging, particularly in older 
cases. SEER’s historic stage is certainly useful, but AJCC 
staging information provides much finer classifications and is 
the basis of modern clinical decision making and prognostic 
FIGURE 2.  Five-year conditional 
cause-specific survival of esophageal 
cancer patients by American Joint 
Committee on Cancer (AJCC) 6th 
edition stage, calculated from Kaplan–
Meier survival estimates, with diagonal 
labels above the bars showing cause-
specific survival from diagnosis.
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assessment. For esophageal cancer in the SEER registry, 
AJCC stage information is only available as 6th edition for 
cases diagnosed during or after 2004. The quality of diagnos-
tic procedures may have led to understaging of patients, which 
could artificially inflate the survival of more advanced stages.
Subanalysis of conditional overall survival using only 
this subgroup diagnosed during 2004 to 2011 found the 
same conclusion as using SEER historic stage. Because 
of recent data with limited follow-up, conditional survival 
could only be calculated up to 3 years after diagnosis for 
this subanalysis, and stages III and IV in particular had 
very small sample sizes (111 and 53 at risk after 3 years) 
because of the poor survival of advanced stages, resulting in 
potentially less representative results. Follow-up time is par-
ticularly important for conditional survival because the con-
ditional survival calculated at the 2-year mark, for instance, 
requires follow-up information until at least 7 years after 
diagnosis. The SEER registry is a useful resource because it 
has long-term follow-up information for many tumor types, 
including esophageal cancer.
FIGURE 3. A,  Five-year conditional 
overall survival (A) and cause-specific 
survival (B) of esophageal cancer 
patients by grade, calculated from 
Kaplan–Meier survival estimates, with 
diagonal labels above the bars show-
ing overall survival and cause-specific 
survival from diagnosis, respectively.
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CONCLUSIONS
This is the first known study of conditional survival 
for esophageal cancer. Conditional overall and cause-specific 
survivals here provide visual and quantitative evidence of the 
changing prognosis of a patient over time. Patients with more 
advanced stages in particular can feel encouraged by their 
improving prognosis with every year survived. Conditional 
survival is a valuable resource in cancer survivorship and 
should continue to be investigated with other databases with 
more treatment and staging information and longer follow-up. 
In summary, conditional survival can be a useful tool to pre-
dict survival for esophageal patients, their family and friends, 
and healthcare professionals.
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